Relmada’s Phase III Depression Study Scuppered By ‘Placebo Paradox’

Adjunctive Studies Will Continue

 
• By Andrew McConaghie

An unexpectedly strong response in the placebo arm has derailed a monotherapy study of Relmada’s investigational antidepressant REL-1017, but the company will continue its trials as an adjunctive therapy.

Brain cloud jigsaw
After years of no new therapies, major depressive disorder is seeing advances again. • Source: Shutterstock

More from Neurological

More from Therapy Areas